GLP-1 medications, long-established as treatments for type 2 diabetes, are now recognised as highly effective treatments for managing obesity. In this episode of the Clinical Update podcast, Professor John Wilding talks to Dawn Liz Powell about how evidence is building for new ways to support people living with obesity.
As well as the development of subcutaneous and oral GLP-1 medications and how they work, Professor Wilding discusses their current role in the management of type 2 diabetes and obesity, their potential additional benefits (such as cardiovascular risk reduction), and their possible side-effects.
Looking to the future, he says that there are ‘over 50 drugs in either phase II or phase III development’ including amylin analogues, triple analogues, and a monthly GLP-1/GIP antibody injection.
Educational objectives
After listening to this podcast, healthcare professionals should be more aware of:
- How GLP-1 medications work for both type 2 diabetes and for obesity
- Their current role in the management of obesity
- The risks and benefits of GLP-1 medications
- What new oral preparations for weight loss are emerging
- New and combination medications that may be available in the future
You can access the website version of this podcast, along with key learning points, on MIMS Learning. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser and note-taking for appraisal.
Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.
MIMS Learning
Obesity in adults
Obesity and pregnancy
Obesity podcourse with Dr Patrick Holmes, part 1: metabolic vulnerability
Obesity podcourse with Dr Patrick Holmes, part 2: established metabolic disease
Obesity podcourse with Dr Patrick Holmes, part 3: obesity and multiple comorbidities
MIMS
Obesity treatments
Hosted on Acast. See acast.com/privacy for more information.